(ALXO) ALX Oncology Holdings Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ALXO) ALX Oncology Holdings Inc. Complete Analysis Pack
Unlock Strategic Clarity
This ALX Oncology Holdings Inc. 4P's Marketing Mix Analysis summarizes the company’s product offerings, pricing approach, distribution channels, and promotional tactics in a concise, actionable format; the page includes a genuine preview/sample of the analysis so you can review style and content before buying—purchase the full version to obtain the complete, ready-to-use report.
Product
ALX148 lead candidate
ALX148 is ALX Oncology Holdings Inc.’s lead immuno-oncology candidate and its main value driver. It is a CD47 blocking agent, a target used by cancer cells to hide from immune attack. As of July 2026, it remains the company’s core development asset, so progress here matters most for the pipeline and investor view.
Phase 1b/2 clinical stage
ALX148 is still in Phase 1b/2, so ALX Oncology Holdings Inc. is testing safety, dose, and early efficacy before any launch. That makes the product a mid-stage asset, not a commercial one.
ALX Oncology Holdings Inc. has not yet commercialized ALX148, so the product has no product sales and its value still depends on clinical results.
For the 4P's, this means the product strategy is still tied to data generation, with success measured by trial readouts, not market share.
Hematologic malignancies
ALX Oncology Holdings Inc. is advancing its hematologic malignancies program in myelodysplastic syndromes, acute myeloid leukemia, and non-Hodgkin’s lymphoma, three blood cancers with high unmet need. MDS affects about 20,000 people a year in the U.S., AML has about 20,000 new U.S. cases a year, and NHL causes roughly 80,000 new U.S. cases, supporting a focused oncology-first position. MDS can progress to AML in about 30% of patients, which sharpens the need for better therapies.
Solid tumor indications
ALX148 is being tested across at least 4 solid-tumor settings, including head and neck squamous cell carcinoma, HER2-positive gastric/gastroesophageal junction carcinoma, and HER2-expressing breast cancer. That wide spread of indications raises the odds of finding a clear clinical niche. For ALX Oncology Holdings Inc., it also broadens the asset’s possible market reach beyond one cancer type.
- 3 named solid tumors
- 1+ other solid-tumor settings
- Broader clinical utility
ALTA-002 preclinical pipeline
ALTA-002 is ALX Oncology Holdings Inc.'s preclinical SIRPa TRAAC program, built to activate both innate and adaptive immunity. It expands the pipeline beyond ALX148, giving the Company a second shot at value creation before clinical proof of concept. As a Product, its role is clear: broaden the lead asset story and support longer-term pipeline depth.
- Preclinical SIRPa TRAAC program
- Engages innate and adaptive immunity
- Second asset beyond ALX148
ALX Oncology’s Fate Hinges on ALX148 Clinical Readouts
ALX Oncology Holdings Inc.’s Product mix is still led by ALX148, a Phase 1b/2 CD47 blocker with no product sales yet; its value still hinges on clinical readouts, not revenue. The program spans hematologic and solid tumors, including MDS, AML, and NHL, plus multiple solid-tumor settings. ALTA-002 adds a preclinical second asset and gives Company Name pipeline depth.
| Asset | Status | Role |
|---|---|---|
| ALX148 | Phase 1b/2 | Lead asset |
| ALTA-002 | Preclinical | Pipeline depth |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific 4P’s analysis of ALX Oncology Holdings Inc.’s product, pricing, place, and promotion strategies in market context.
Editable Excel File
Condenses ALX Oncology’s 4Ps into a quick, decision-ready snapshot that simplifies strategy review and internal alignment.
Reference Sources
Provides a concise, traceable bibliography of industry reports, clinical data, and regulatory filings to speed due diligence and verify ALX Oncology assumptions.
Place
South San Francisco headquarters
ALX Oncology Holdings Inc. is headquartered in South San Francisco, California, in the heart of the Bay Area biotech hub. The city is home to 200+ life-science companies and sits near UCSF, Stanford, and major CRO and CDMO networks, which helps hiring, partnerships, and trial execution. That location also supports fast access to skilled labor and clinical-development services.
Clinical trial site network
ALX Oncology Holdings Inc. sells ALX148 only through clinical trial sites, not retail pharmacies, so its "place" is a network of investigator-led and sponsor-run study centers. As a clinical-stage biotech with no approved product, access depends on trial enrollment and site activation, which directly shapes patient reach.
This makes trial geography the core distribution channel, with centers chosen for oncology expertise and patient volume. The model keeps ALX148 in controlled studies, where dosing, safety, and efficacy data are collected before any commercial launch.
Merck Phase 2 collaboration
ALX Oncology Holdings Inc.'s Merck Phase 2 collaboration centers on evorpacept (ALX148) plus pembrolizumab, with or without chemotherapy, in head and neck cancer. Merck reported Keytruda sales of $29.5 billion in 2024, so this pairing taps a proven immuno-oncology backbone. It also needs trial sites that can deliver combination regimens, which widens ALX Oncology Holdings Inc.'s clinical reach.
Zymeworks Phase 1 collaboration
ALX148 is in a Phase 1 study with Zymeworks’ zanidatamab for HER2-expressing breast cancer and other solid tumors, giving ALX Oncology Holdings Inc. another clinical access path. The route is partner-led, since Zymeworks helps open trial sites and patient access. That makes distribution site-based, not direct-to-market.
- Phase 1 combo study
- HER2-expressing tumors
- Partner-led access
- Site-based trial route
Tallac, Selexis, Crystal agreements
ALX Oncology Holdings Inc. uses Tallac Therapeutics, Selexis SA, and Crystal Bioscience agreements to widen development, manufacturing, and commercialization reach. These partner links push the technology into outside channels, so ALX Oncology can scale without building every step alone. The setup matters because its lead pipeline still depends on partnered science and external manufacturing capacity.
- 3 partner agreements widen reach
- Support development and manufacturing
- Help commercialization through channels
ALX Oncology’s Trial-Site Model Taps Merck’s $29.5B Keytruda Scale
ALX Oncology Holdings Inc. uses a site-based "place" model: headquarters in South San Francisco and clinical access through oncology trial centers, not pharmacies. Its Merck Phase 2 study and Zymeworks Phase 1 study widen reach through partner-run sites, while 2024 Merck Keytruda sales of $29.5 billion show the scale of the backbone it plugs into.
| Place factor | Data |
|---|---|
| HQ | South San Francisco |
| Core channel | Clinical trial sites |
| Merck FY2024 sales | $29.5 billion |
Preview the Actual Deliverable
ALX Oncology Holdings Inc. Reference Sources
The preview shown here is the actual ALX Oncology Holdings Inc. 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises.
This is the same ready-made, fully complete Marketing Mix document you'll download immediately after checkout, editable and ready to use.
You're viewing the exact version of the analysis you'll own upon purchase—comprehensive, high-quality, and final.
Promotion
Clinical trial disclosures
ALX Oncology uses clinical-trial disclosures to promote evorpacept, highlighting phase, indication, and combo-therapy data from studies in HER2-positive and blood cancers. These updates matter because they turn pipeline progress into proof points for clinicians, investors, and partners. In 2025, the company reported a cash position of about $200 million, giving added weight to each trial readout.
Merck partnership publicity
Merck partnership publicity is a strong promotion lever for ALX Oncology Holdings Inc. The Phase 2 pembrolizumab study gives ALX148 outside validation from Merck, the maker of Keytruda, which posted $29.5 billion in 2024 sales and still anchors global oncology care. That link lifts ALX Oncology Holdings Inc.'s visibility with doctors, investors, and partners.
Zymeworks collaboration messaging
ALX Oncology can use Zymeworks collaboration messaging to point to the Phase 1 zanidatamab combo study as a second public proof point. That matters because combo trials help show both differentiation and scientific breadth in HER2-driven cancers, a space that includes about 15%-20% of breast cancers.
For 2025-2026 promotion, this kind of data-backed tie-up helps make the story more credible than a single asset claim.
Scientific and investor relations
ALX Oncology Holdings Inc. promotes through science-first channels, not consumer ads, because it is still a clinical-stage biotech. It uses press releases, conference talks, and investor decks to keep ALX148 and the rest of the pipeline in front of analysts and shareholders. The message is simple: show trial progress, safety data, and next milestones.
That mix fits a company with no commercial product sales and a burn-driven model, so each update matters for valuation and funding confidence. Investor relations is the main promotion engine, and the goal is to support the stock with credible clinical readouts rather than broad brand marketing.
- Press releases drive trial updates.
- Conference data builds credibility.
- Investor decks keep focus on pipeline.
- No consumer advertising is needed.
Licensing and development announcements
ALX Oncology Holdings Inc. uses licensing and development announcements with Tallac Therapeutics, Selexis SA, and Crystal Bioscience to show its platform can be extended beyond one program. These deals signal technical depth in antibody engineering, cell line work, and biologics development, which matters in a market where biotech cash burn and execution risk stay high. Such news helps support stakeholder trust when the company is still advancing its pipeline.
- Signals platform expansion
- Shows outside technical validation
- Supports partner and investor confidence
Evorpacept Updates Help Sustain ALX Oncology Funding Confidence
ALX Oncology Holdings Inc. promotes evorpacept with clinical-readout news, conference talks, and investor decks, since it has no product sales. The 2025 cash balance was about $200 million, so each update matters for funding confidence. Partner links with Merck and Zymeworks add third-party credibility.
| Promotion lever | 2025-2026 fact |
|---|---|
| Clinical updates | Phase and combo data |
| Cash support | About $200 million |
| Partner validation | Merck, Zymeworks |
Price
No commercial list price
As of July 2026, ALX Oncology Holdings Inc. has no approved marketed product, so there is no public retail or list price for ALX148 or ALTA-002. Pricing is not yet a customer-facing issue because both assets remain in development. In 2026, the company’s value is tied to clinical progress, not product pricing.
Clinical-stage pre-revenue model
ALX Oncology Holdings Inc. remains clinical-stage and pre-revenue, so pricing is not yet the main driver of value. With 0 commercial product sales, the market focus stays on trial readouts, FDA progress, and partner interest. In this model, each positive data update can matter more than near-term price, because pipeline success is what can create future revenue.
Research and collaboration funding
ALX Oncology Holdings Inc. leans on collaborations and licensing deals to fund development, so its "pricing" economics are really partner-funded R&D economics. These agreements can help offset trial, manufacturing, and study costs, which matters while the Company is still pre-commercial. In the latest reported period, the Company had no product revenue, so outside funding remains the main cash buffer.
Trial-access not patient retail pricing
For ALX Oncology Holdings Inc., "price" is not a patient retail tag because evorpacept is still given in clinical trials, not sold commercially. The cost is set by sponsors, sites, and study contracts, so the real pricing issue is trial finance, not market pricing. With no approved product sales in FY2025, the number that matters is research spend, not pharmacy checkout price.
- Clinical-trial supply, not retail sale
- Sponsors and sites fund the cost
- Price is a trial-finance issue
Future oncology pricing TBD
If ALX148 or another ALX Oncology Holdings Inc. candidate wins approval, future pricing would likely sit in specialty oncology biologic territory, where U.S. launch prices often run in the six-figure annual range. Final pricing will hinge on efficacy, safety, payer access, and how it stacks up against competing antibody-based therapies.
As of July 2026, ALX Oncology Holdings Inc. has not set or publicly disclosed a price for any approved oncology asset.
- Specialty oncology biologic pricing likely if approved
- Exact price still not publicly set
- Depends on efficacy, safety, access, competition
ALX Oncology Has No FY2025/FY2026 Approved Product Pricing Yet
ALX Oncology Holdings Inc. has no approved product in FY2025/FY2026, so there is no public list price for evorpacept or ALTA-002. Price is still a clinical-trial cost issue, funded by sponsors and partners, not a patient checkout price. If approval comes, pricing would likely fall in specialty oncology biologic ranges.
| Item | FY2025/FY2026 |
|---|---|
| Commercial product price | None disclosed |
| Product revenue | 0 |
| Pricing driver | Clinical progress |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.